Appendix 4C Revised
Filed with ASX · · 12 pages · English
On 6ix: 6ix.com/news/appendix-4c-revised
• Record $18.4 million quarterly Cash Receipts, representing a 149% increase on Q2 FY25 and a 43% increase on Q1 FY26. • $2.5 million positive Q2 cash flow from operating activities • Completed dual listing on the Frankfurt Stock Exchange (ticker: PR8.F) on 13 October 2025, enhancing liquidity and access for European investors • Executed exclusive import, manufacture, and supply agreement with Cur
In the deck
Story so far
Earlier from Bioxyne
- Quarterly Activities/Appendix 4C Cash Flow Report
- Supply Agreement Secured - Central American Cannabis Markets
- Funding from SOSE to Establish UK GMP Manufacturing Facility
- BLS to Manufacture and Distribute Curaleaf International MID
- Presentation on FY2025 Quarter 1 Results
Later from Bioxyne
- Presentation Results Q2 FY2026
- Half Yearly Report and Accounts
- Stronger H1 FY2026 Performance Upward Revision to Guidance
- BXN H1 FY2026 Results Presentation
- Bioxyne Signs Manufacturing Agreement with Aurora Cannabis
Follow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne